Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) is expanding enrollment and broadening the clinical development strategy for its investigational WEE1 inhibitor APR-1051 as the company advances a Phase 1 …
Aprea Expands APR-1051 Trial as Enrollment Accelerates Read More DOYLESTOWN, PA — Aprea Therapeutics reported early signs of anti-tumor activity from its ongoing Phase 1 trial of experimental cancer therapy APR-1051, with partial responses observed in patients with advanced …
Aprea Reports Early Tumor Responses in Phase 1 APR-1051 Study Read More DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) is expanding enrollment in a Phase 1 study of its experimental cancer drug APR-1051 after early clinical data showed tumor responses and disease …
Aprea Expands Cancer Trial After Early Tumor Responses Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) said it will expand enrollment in its lead cancer drug trial after closing an oversubscribed $30 million private placement, as early patient …
Aprea Expands Cancer Trial After $30 Million Financing Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will present early results from a Phase 1 clinical trial of its WEE1 inhibitor APR-1051 at the 2026 American Society of Clinical …
Aprea Abstract Accepted for ASCO on APR-1051 Phase 1 Study Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported a confirmed partial response in its ongoing Phase 1 clinical trial evaluating APR-1051, a WEE1 kinase inhibitor, in patients with biomarker-defined …
Aprea Reports Partial Response in APR-1051 Cancer Trial Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) reported its fourth-quarter and full-year 2025 financial results and said early clinical data from its ongoing Phase 1 trial of APR-1051 showed …
Aprea Reports 2025 Results, Early Data for APR-1051 Trial Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial showing a second unconfirmed partial response in a patient with advanced …
Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) said its president and chief executive officer, Oren Gilad, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences …
Aprea to Present at Oppenheimer Healthcare Conference Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. has appointed veteran physician-scientist Eugene (Gene) Kennedy, MD, as chief medical advisor, strengthening its leadership team as the biotechnology company advances a promising new …
Aprea Taps Veteran Oncologist as Clinical Momentum Builds for Lead Cancer Drug Read More